Chiral anticancer drugs are the subject of ongoing research due to their optical characterization and pharmacological effects.Achieving a single enantiomer of a chiral anticancer drug is arduous,but it can significant...Chiral anticancer drugs are the subject of ongoing research due to their optical characterization and pharmacological effects.Achieving a single enantiomer of a chiral anticancer drug is arduous,but it can significantly improve its pharmacokinetics for tumor therapy.Here,the chiral nanocatchers,known as Dbiotin-P5■MCC NCs,were designed and prepared based on host-vip self-assembly between D-biotin anchored pillar[5]arene(D-biotin-P5)and myristoyl chloride choline(MCC).D-Biotin-P5■MCC NCs featuring the chiral separation and enzyme-induced disassemble were evaluated for their ability to selectively capture and subsequently target the release of(R,R)-OXA enantiomers into tumor cells.Furthermore,the use of D-biotin-P5■MCC NCs has demonstrated a significant enhancement in the intracellular uptake of OXA,with the drug being efficiently released to MCF-7 breast cancer cells.This has led to a superior inhibitory effect on MCF-7 cells when compared to free OXA,while also reducing the cytotoxicity of the drug in HEK 293 human embryonic kidney cells.This research not only paves a promising way for the fabrication of chiral supramolecular nanocarriers but also holds the potential to improve the processes of chiral drug separation and targeted therapy.展开更多
基金supported by the National Natural Science Foundations of China(Nos.22464022,22461048,and 22364023)Scientific Research Fund Project of Yunnan Education Department(No.2023j0204)+3 种基金Yunnan Normal University Doctoral Research Initiation Program(No.01100205020503180)Xing Dian Talent Support Program Foundations(No.01100208019916016)Yunnan Normal University Graduate Research Innovation Fund Project(No.YJSJJ23-B87)Yunnan Basic Research Funding Program(Nos.202401AT070128,202301AT070074,and 202201AU070056)。
文摘Chiral anticancer drugs are the subject of ongoing research due to their optical characterization and pharmacological effects.Achieving a single enantiomer of a chiral anticancer drug is arduous,but it can significantly improve its pharmacokinetics for tumor therapy.Here,the chiral nanocatchers,known as Dbiotin-P5■MCC NCs,were designed and prepared based on host-vip self-assembly between D-biotin anchored pillar[5]arene(D-biotin-P5)and myristoyl chloride choline(MCC).D-Biotin-P5■MCC NCs featuring the chiral separation and enzyme-induced disassemble were evaluated for their ability to selectively capture and subsequently target the release of(R,R)-OXA enantiomers into tumor cells.Furthermore,the use of D-biotin-P5■MCC NCs has demonstrated a significant enhancement in the intracellular uptake of OXA,with the drug being efficiently released to MCF-7 breast cancer cells.This has led to a superior inhibitory effect on MCF-7 cells when compared to free OXA,while also reducing the cytotoxicity of the drug in HEK 293 human embryonic kidney cells.This research not only paves a promising way for the fabrication of chiral supramolecular nanocarriers but also holds the potential to improve the processes of chiral drug separation and targeted therapy.
